{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"retatrutide","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/retatrutide/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/retatrutide/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/retatrutide/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"retatrutide","title":"Retatrutide: the third receptor, and what the evidence now establishes","register":"accessible","tags":["peptide","retatrutide","glp-1","obesity","disc"],"updated_at":"2026-08-05T02:14:48.127Z","body_excerpt":"Retatrutide is one molecule that switches on three different hormone receptors at once: GLP-1, GIP, and glucagon. Semaglutide hits one of those. Tirzepatide hits two. Retatrutide adds the third, and that third one is the interesting part, because glucagon is the hormone most people know as the one that raises blood sugar — the opposite of what a diabetes drug is supposed to do.\n\nUnderstanding why adding it works is most of understanding this drug.\n\n**Where the evidence stands, before anything else.** Retatrutide has been tested in people. Phase 2 randomised trials in obesity and in type 2 diabetes are published, and the first phase 3 trial — a double-blind randomised trial in type 2 diabetes — has now reported. The obesity phase 3 trials and the cardiovascular and kidney outcome trials are still running. It is not an approved medicine in any country, so nothing sold under this name is the material that was studied.\n\n## Why putting glucagon into a weight-loss drug is not a mistake\n\nGlucagon does raise blood sugar. It also does something else: it increases energy expenditure. It tells the liver to break down stored fat and it raises the rate at which the body burns energy at rest.\n\nSo a molecule that activates the glucagon receptor on its own would burn more energy and worsen blood sugar. A molecule that activates GLP-1 and GIP lowers blood sugar strongly and reduces appetite. Put all three on one peptide and the GLP-1 and GIP arms more than cover the blood sugar cost of the glucagon arm, and you keep the extra energy expenditure.\n\nThe result is a drug that attacks weight from both sides at once — appetite down and energy out up — rather than appetite alone. Every other drug in this class works mainly on the intake side.\n\nThe elegance of that design has been demonstrated in an unusual way. Researchers testing the components in mice engineered to have no working GLP-1 receptor at all found that retatrutide still normalised body weight in those animals.\n\n[[embed:source:s11]]\n\nThat is a mechanistic result rather than a clinical one, and it matters because it isolates the contribution of the other two arms. The weight effect is not simply a stronger version of what GLP-1 drugs do.\n\n## What it actually does to weight, in numbers\n\nThe comparison that puts it in context is a network analysis of the drugs acting on the glucagon receptor, which ranks them against placebo on weight.\n\n[[embed:source:s12]]\n\nRetatrutide produced the greatest weight reduction of the class — a mean difference of 13.44 kg against placebo, ahead of survodutide at 10.74 kg, with cotadutide's effect small and not statistically significant.\n\nThe same analysis found retatrutide had the largest effect on HbA1c, the three-month average blood sugar measure — and it was the only one of the four whose effect on HbA1c reached statistical significance.\n\nIn the type 2 diabetes programme the blood sugar numbers are striking on their own terms: HbA1c improved by 2.2%, and 82% of participants reached 6.5% or below — a threshold at which many people would no longer meet the diagnostic criteria for diabetes.\n\n[[embed:source:s13]]\n\nThe same summary reports improvements across blood pressure, lipids, waist circumference, and an 82% reduction in liver fat.\n\n## The body composition question, answered directly\n\nThe standard objection to very effective weight-loss drugs is that a large fraction of what is lost is muscle rather than fat. It is a serious objection, particularly in older people, and the more weight a drug takes off the more it matters.\n\nA substudy measured body composition directly rather than inferring it.\n\n[[embed:source:s14]]\n\nFat mass fell 26.1% on the 8 mg dose and 23.2% on 12 mg, against 2.6% on placebo. And on the question people actually want answered:\n\n[[embed:source:s15]]\n\nThe proportion of the loss that was lean mass was similar to other obesity treatments. Retatrutide takes off more total weight, and it does not appear to take off a disproportionate share of ","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"rc-safety","text":"Adverse events are the dose-dependent incretin profile — nausea, diarrhea, vomiting; a safety review found the profile acceptable but did not establish long-term safety.","tier":"human","slot":"limitations","interaction_risk":false,"status":"active","source_ids":["s2","s4"],"why_material":"Names the known harms and their dependence on dose.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"rc-phase3","text":"The Phase 3 TRIUMPH program is ongoing and retatrutide is not approved by any regulator as of writing; everything here is investigational trial data.","tier":"runtime","slot":"limitations","interaction_risk":false,"status":"active","source_ids":["s8","s7"],"why_material":"Bounds the evidence — no approval, no completed Phase 3.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.1,"quote_gated":false},{"id":"rc-ruo","text":"This is a research-use-only compound. The article reports trial data; it is not medical advice and does not establish a treatment for any person.","tier":"runtime","slot":"limitations","interaction_risk":false,"status":"active","source_ids":[],"why_material":"Compliance and reader-safety boundary.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.1,"quote_gated":false},{"id":"rc-obesity","text":"In adults with obesity, meta-analysis finds retatrutide produces large, dose-dependent body-weight reductions, statistically and clinically superior to placebo, with the highest doses approaching ~24% at ~48 weeks.","tier":"human","interaction_risk":false,"status":"active","source_ids":["s3","s4"],"why_material":"The headline efficacy claim, graded to pooled human data.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"rc-t2d","text":"In type 2 diabetes, a Phase 2 substudy found retatrutide significantly improved total body-fat-mass reduction versus both placebo and dulaglutide.","tier":"human","interaction_risk":false,"status":"active","source_ids":["s6"],"why_material":"Efficacy beyond obesity, in a controlled comparison.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"rc-mech","text":"Retatrutide is a single synthetic peptide that agonizes three receptors at once — GLP-1, GIP, and glucagon (GCGR).","tier":"mechanistic","slot":"what_it_is","interaction_risk":false,"status":"active","source_ids":["s8"],"why_material":"Defines what the compound is and why it differs from dual agonists.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"rc-mech2","text":"Glucagon-receptor agonism raises energy expenditure and hepatic fat oxidation, adding an energy-output arm on top of the appetite-suppressing GLP-1/GIP arms.","tier":"mechanistic","interaction_risk":false,"status":"active","source_ids":["s5"],"why_material":"Explains the mechanistic rationale for the third receptor.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/","title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","quote":"The primary endpoint was the change in HbA1c concentration from baseline to week 40.","summary":"TRANSCEND-T2D-1, Lancet 2026: the first published phase 3 trial of retatrutide — double-blind and randomised, in people with type 2 diabetes not controlled by diet and exercise. Baseline mean HbA1c 7.9%, mean BMI 35.8.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"39e270374cddb740a5f1805210a916616aeef86019754eb746b0a40df8128677"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40728138/","title":"Efficacy and safety of retatrutide for the treatment of obesity","quote":"This systematic review assessed the safety and efficacy of retatrutide for obesity treatment using available clinical trial data.","summary":"2025 systematic review on retatrutide safety/efficacy for obesity.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"66cb586a5c30653d670a0baf7f53c9c248e780f0832a0676815ac2562338b2be"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39817343/","title":"Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis","quote":"In conclusion our analysis found retatrutide to be clinically and statistically better than placebo in the various studies outcomes.","summary":"2025 meta-analysis showing retatrutide superior to placebo for obesity.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"f80e4f94a8b49e16ebf8fdd80e5ad5711cc77649e284d560a66d7b922e334297"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40291085/","title":"Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist, for the treatment of obesity: a systematic review and meta-analysis","quote":"Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.","summary":"2025 meta-analysis on retatrutide for obesity treatment.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"847a5721780ed669c07ef7c7bbe403157a66903703893c8aacae277967a4e179"},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40563436/","title":"Retatrutide-A Game Changer in Obesity Pharmacotherapy","quote":"This review synthesizes findings from preclinical and clinical studies, highlighting retatrutide's mechanisms, efficacy, and safety profile.","summary":"2025 review on retatrutide mechanisms, efficacy, and safety.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"767010d787ad1410724e3f72a0db6f9267b03c9b1a97cb39ee618a031a66c722"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40609566/","title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","quote":"In adults with type 2 diabetes, retatrutide significantly improved total body fat mass reduction compared with placebo and dulaglutide.","summary":"2025 phase 2 substudy on retatrutide effects on body composition in T2D.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"f9dec1ff1843db8b4db3e1aeda00a2c5c534dedc4230a3c9d89251bb17a26f24"},{"id":"s7","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT05882045","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)","quote":"The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease.","summary":"Ongoing TRIUMPH-3 phase 3 trial (last update 2026) for retatrutide in obesity with CVD.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"894fa5a96c21023b1d64039a3626257d6ba00a6a0923708758b65bb5e9ed553b"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41090431/","title":"Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials","quote":"Retatrutide, a novel synthetic molecule, is a triple agonist activating the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors. The TRIUMPH clinical development program evaluates its safety and efficacy concurrently for the treatment of obesity and two related complications-obstructive sleep apnea (OSA) and knee osteoarthritis (OA). A novel basket trial design simultaneously evaluates retatrutide treatment across these multiple adiposity-related disease states.","summary":"Describes the design of Phase 3 TRIUMPH trials for retatrutide in obesity, OSA, and knee OA using a basket trial approach.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"eb3e21dd33e63e06263cffd93dfdb3653fa6dbd6cca89117745af2da2bfcc884"},{"id":"s9","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT05936151","title":"A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes","quote":"The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D).","summary":"Phase 2b trial examining retatrutide's impact on renal function in overweight/obese patients with CKD ± T2D.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"ebbac8c3296c337e13dd663e33d17d9b6ffe9bb434c004cb60fe470e49054ae3"},{"id":"s10","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT07232719","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)","quote":"The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.","summary":"Phase 3b trial of retatrutide vs placebo for weight reduction in obesity/overweight without T2D.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"a767fd2c0ecd15f1406073dc1a969b13a3237c971f378da42aad18e8bc7fcb0c"},{"id":"s11","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41997446/","title":"GIPR:GCGR co-agonism restores normal weight in obese rodents","quote":"Retatrutide a balanced GLP-1R:GIPR:GCGR triagonist normalized body weight in obese GLP-1R KO mice.","summary":"Molecular Metabolism 2026: obesity was reversed in mice with no working GLP-1 receptor at all, isolating what the GIP and glucagon arms contribute. A mechanistic result, not a clinical one.","claim_ids":[],"hash":"a765e6ad75fa03829c75d78bec6cc921cb3415412f31455b1f6aef79d25c3f33"},{"id":"s12","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41787737/","title":"Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials","quote":"Retatrutide demonstrated the greatest weight reduction versus placebo (MD -13.44 kg; 95% CI [-18.38, -8.51]), followed by survodutide (MD -10.74 kg; 95% CI [-15.68, -5.80]","summary":"Endocrinology, Diabetes & Metabolism 2026: a network comparison of the glucagon-receptor drugs. Retatrutide led on weight and on HbA1c, and was the only one of four whose HbA1c effect reached statistical significance.","claim_ids":[],"hash":"74be946afbee8ee645a7f0e95059c9ee8ac7501ffc2a9658d868850854897acb"},{"id":"s13","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40741227/","title":"Triple Agonism Based Therapies for Obesity","quote":"In the T2D study, HbA1c improved by 2.2%, with 82% of participants reaching HbA1c ≤ 6.5%.","summary":"Current Cardiovascular Risk Reports 2025: the diabetes results, alongside improvements in blood pressure, lipids, waist circumference and an 82% reduction in liver fat.","claim_ids":[],"hash":"cdb47984aca1cc23f8a7659ae840a2f68f096cd9dd1b65e82ea65f7a5dbabde6"},{"id":"s14","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40609566/","title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","quote":"Percent reduction from baseline in total fat mass was 4·9% (SE 1·4%) with retatrutide 0·5 mg, 15·2% (3·2%) with retatrutide 4 mg (pooled), 26·1% (2·5%) with retatrutide 8 mg (pooled), 23·2% (3·0%) with retatrutide 12 mg, 2·6% (1·6","summary":"Lancet Diabetes & Endocrinology 2025: body composition measured directly rather than inferred. Manufacturer-funded, and 85% of participants were White.","claim_ids":[],"hash":"76dac7c5455e1d91a268ba6a445d0b2bf5b41e6e172c8a38098846f1b54fd980"},{"id":"s15","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40609566/","title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","quote":"The proportion of lean mass loss to weight loss was similar to other obesity treatments.","summary":"The same substudy on the standard objection to very effective weight drugs: more total weight comes off, and the share of it that is muscle is not disproportionate.","claim_ids":[],"hash":"5e728380c6628f75e916098b674f72427d32a5e6fb816d1e0b1f4f4a30d78321"},{"id":"s16","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41831086/","title":"Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes","quote":"An expanding pipeline of dual glucagon/GLP-1 and triple GIP/GLP-1/glucagon agonists such as retatrutide has shown marked reductions in liver fat and signals of MASH benefit.","summary":"Current Diabetes Reports 2026: fatty liver disease has only two specifically approved drugs, which is the context for how large the liver fat result is.","claim_ids":[],"hash":"9fe1f80a88af676131ba4635d1d6368a31fe06cabde3efa2a5b76cd2306ac028"},{"id":"s17","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42195239/","title":"Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression","quote":"These therapies may also exert beneficial effects on fibrosis progression; however, the currently available evidence remains limited.","summary":"Medicina 2026: the distinction that decides whether this becomes a liver drug — reducing fat in the liver is not the same as changing the scarring that fat drives.","claim_ids":[],"hash":"8b06faef02e21781983a0089d6c4ba36864fb9cc0de7e735a607aa1a99777b24"},{"id":"s18","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40916752/","title":"Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study","quote":"On average, people who experienced greater weight reduction also reported being less hungry and less likely to overeat.","summary":"Diabetes, Obesity & Metabolism 2025: the first study of appetite and eating behaviour on this drug. The people reporting the biggest hunger changes were the same people losing the most weight.","claim_ids":[],"hash":"9d9659b988d0f149cf0334855f280d596f2b07ab9094c61470dade787f98e93d"},{"id":"s19","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40741227/","title":"Triple Agonism Based Therapies for Obesity","quote":"Gastrointestinal symptoms were the most common side effects; no major safety concerns were observed.","summary":"The phase 2 safety picture. Phase 2 enrols hundreds of people for months — rare and long-term harms are not what it is built to detect.","claim_ids":[],"hash":"9a4af7e86f4b1875439d2ff8ad4c9bb53736b26d80756f6e3b1501ab23696277"},{"id":"s20","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40988099/","title":"Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","quote":"Pancreatic cancer and GLP-1 RA use showed no significant association (RR: 1.30, 95% CI 0.86-1.97).","summary":"Endocrinology, Diabetes & Metabolism 2025: a class-level finding for GLP-1 receptor agonists — slightly increased pancreatitis risk, no significant pancreatic cancer association. An inference for retatrutide from shared mechanism, not a measurement of it.","claim_ids":[],"hash":"5ca283da647c1cc730630d2e374aadd73bde8f5fed21a6b7e7eaa2ba42688ee9"},{"id":"s21","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40741227/","title":"Triple Agonism Based Therapies for Obesity","quote":"A comprehensive phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes in people with obesity and/or T2D.","summary":"Where the drug actually is: phase 2 complete, phase 3 running, cardiovascular and kidney outcomes not yet reported.","claim_ids":[],"hash":"cd0cad1435cf84fad1e7fac4fb2f1f9f6e906fd55bd3bc629b2e9f7e6655015a"},{"id":"s22","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41545327/","title":"The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities","quote":"Phase 2 trials report unprecedented weight reductions, comparable to bariatric surgery, with additional benefits for metabolic comorbidities such as NASH and cardiovascular disease.","summary":"Clinical Pharmacology in Drug Development 2026: a perspective calling the drug a watershed, written before any phase 3 result exists. Included as an example of the register these results attract.","claim_ids":[],"hash":"701b135b037d228e2b1825bb811eacfea9aac9936ab3b86f5127007bc4ad3409"},{"id":"s23","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41297910/","title":"Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders","quote":"These agents offer broad clinical utility beyond glucose lowering by mimicking the pleiotropic hormonal responses observed after bariatric surgery.","summary":"Clinical and Molecular Hepatology 2026: why the effects are this large. These molecules copy the several-hormone response the body produces after bariatric surgery rather than amplifying one signal.","claim_ids":[],"hash":"0d986402992fb62d477f25f9b6b7d6e3a4634c0581336bb174bc231f56fd551b"},{"id":"s24","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/","title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","quote":"490 (91%) participants completed the treatment period on study drug and 504 (94%) completed the study.","summary":"The same phase 3 trial's retention figures. For a drug whose main side effects are gastrointestinal, 91% completing on the study drug is itself a tolerability result.","claim_ids":[],"hash":"1ab5e0df5e49b2da3698bbc16b7c9ea5ae2f46b47ea53294e5c4acf46c88b54d"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/","title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","quote":"The primary endpoint was the change in HbA1c concentration from baseline to week 40.","summary":"TRANSCEND-T2D-1, Lancet 2026: the first published phase 3 trial of retatrutide — double-blind and randomised, in people with type 2 diabetes not controlled by diet and exercise. Baseline mean HbA1c 7.9%, mean BMI 35.8.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"39e270374cddb740a5f1805210a916616aeef86019754eb746b0a40df8128677"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40728138/","title":"Efficacy and safety of retatrutide for the treatment of obesity","quote":"This systematic review assessed the safety and efficacy of retatrutide for obesity treatment using available clinical trial data.","summary":"2025 systematic review on retatrutide safety/efficacy for obesity.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"66cb586a5c30653d670a0baf7f53c9c248e780f0832a0676815ac2562338b2be"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39817343/","title":"Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis","quote":"In conclusion our analysis found retatrutide to be clinically and statistically better than placebo in the various studies outcomes.","summary":"2025 meta-analysis showing retatrutide superior to placebo for obesity.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"f80e4f94a8b49e16ebf8fdd80e5ad5711cc77649e284d560a66d7b922e334297"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40291085/","title":"Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist, for the treatment of obesity: a systematic review and meta-analysis","quote":"Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.","summary":"2025 meta-analysis on retatrutide for obesity treatment.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"847a5721780ed669c07ef7c7bbe403157a66903703893c8aacae277967a4e179"},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40563436/","title":"Retatrutide-A Game Changer in Obesity Pharmacotherapy","quote":"This review synthesizes findings from preclinical and clinical studies, highlighting retatrutide's mechanisms, efficacy, and safety profile.","summary":"2025 review on retatrutide mechanisms, efficacy, and safety.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"767010d787ad1410724e3f72a0db6f9267b03c9b1a97cb39ee618a031a66c722"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40609566/","title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","quote":"In adults with type 2 diabetes, retatrutide significantly improved total body fat mass reduction compared with placebo and dulaglutide.","summary":"2025 phase 2 substudy on retatrutide effects on body composition in T2D.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"f9dec1ff1843db8b4db3e1aeda00a2c5c534dedc4230a3c9d89251bb17a26f24"},{"id":"s7","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT05882045","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)","quote":"The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease.","summary":"Ongoing TRIUMPH-3 phase 3 trial (last update 2026) for retatrutide in obesity with CVD.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"894fa5a96c21023b1d64039a3626257d6ba00a6a0923708758b65bb5e9ed553b"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41090431/","title":"Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials","quote":"Retatrutide, a novel synthetic molecule, is a triple agonist activating the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors. The TRIUMPH clinical development program evaluates its safety and efficacy concurrently for the treatment of obesity and two related complications-obstructive sleep apnea (OSA) and knee osteoarthritis (OA). A novel basket trial design simultaneously evaluates retatrutide treatment across these multiple adiposity-related disease states.","summary":"Describes the design of Phase 3 TRIUMPH trials for retatrutide in obesity, OSA, and knee OA using a basket trial approach.","claim_ids":[],"link_status":"ok","quote_status":"verified","hash":"eb3e21dd33e63e06263cffd93dfdb3653fa6dbd6cca89117745af2da2bfcc884"},{"id":"s9","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT05936151","title":"A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes","quote":"The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D).","summary":"Phase 2b trial examining retatrutide's impact on renal function in overweight/obese patients with CKD ± T2D.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"ebbac8c3296c337e13dd663e33d17d9b6ffe9bb434c004cb60fe470e49054ae3"},{"id":"s10","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT07232719","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)","quote":"The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.","summary":"Phase 3b trial of retatrutide vs placebo for weight reduction in obesity/overweight without T2D.","claim_ids":[],"link_status":"ok","quote_status":"unverified","hash":"a767fd2c0ecd15f1406073dc1a969b13a3237c971f378da42aad18e8bc7fcb0c"},{"id":"s11","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41997446/","title":"GIPR:GCGR co-agonism restores normal weight in obese rodents","quote":"Retatrutide a balanced GLP-1R:GIPR:GCGR triagonist normalized body weight in obese GLP-1R KO mice.","summary":"Molecular Metabolism 2026: obesity was reversed in mice with no working GLP-1 receptor at all, isolating what the GIP and glucagon arms contribute. A mechanistic result, not a clinical one.","claim_ids":[],"hash":"a765e6ad75fa03829c75d78bec6cc921cb3415412f31455b1f6aef79d25c3f33"},{"id":"s12","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41787737/","title":"Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials","quote":"Retatrutide demonstrated the greatest weight reduction versus placebo (MD -13.44 kg; 95% CI [-18.38, -8.51]), followed by survodutide (MD -10.74 kg; 95% CI [-15.68, -5.80]","summary":"Endocrinology, Diabetes & Metabolism 2026: a network comparison of the glucagon-receptor drugs. Retatrutide led on weight and on HbA1c, and was the only one of four whose HbA1c effect reached statistical significance.","claim_ids":[],"hash":"74be946afbee8ee645a7f0e95059c9ee8ac7501ffc2a9658d868850854897acb"},{"id":"s13","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40741227/","title":"Triple Agonism Based Therapies for Obesity","quote":"In the T2D study, HbA1c improved by 2.2%, with 82% of participants reaching HbA1c ≤ 6.5%.","summary":"Current Cardiovascular Risk Reports 2025: the diabetes results, alongside improvements in blood pressure, lipids, waist circumference and an 82% reduction in liver fat.","claim_ids":[],"hash":"cdb47984aca1cc23f8a7659ae840a2f68f096cd9dd1b65e82ea65f7a5dbabde6"},{"id":"s14","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40609566/","title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","quote":"Percent reduction from baseline in total fat mass was 4·9% (SE 1·4%) with retatrutide 0·5 mg, 15·2% (3·2%) with retatrutide 4 mg (pooled), 26·1% (2·5%) with retatrutide 8 mg (pooled), 23·2% (3·0%) with retatrutide 12 mg, 2·6% (1·6","summary":"Lancet Diabetes & Endocrinology 2025: body composition measured directly rather than inferred. Manufacturer-funded, and 85% of participants were White.","claim_ids":[],"hash":"76dac7c5455e1d91a268ba6a445d0b2bf5b41e6e172c8a38098846f1b54fd980"},{"id":"s15","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40609566/","title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","quote":"The proportion of lean mass loss to weight loss was similar to other obesity treatments.","summary":"The same substudy on the standard objection to very effective weight drugs: more total weight comes off, and the share of it that is muscle is not disproportionate.","claim_ids":[],"hash":"5e728380c6628f75e916098b674f72427d32a5e6fb816d1e0b1f4f4a30d78321"},{"id":"s16","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41831086/","title":"Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes","quote":"An expanding pipeline of dual glucagon/GLP-1 and triple GIP/GLP-1/glucagon agonists such as retatrutide has shown marked reductions in liver fat and signals of MASH benefit.","summary":"Current Diabetes Reports 2026: fatty liver disease has only two specifically approved drugs, which is the context for how large the liver fat result is.","claim_ids":[],"hash":"9fe1f80a88af676131ba4635d1d6368a31fe06cabde3efa2a5b76cd2306ac028"},{"id":"s17","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42195239/","title":"Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression","quote":"These therapies may also exert beneficial effects on fibrosis progression; however, the currently available evidence remains limited.","summary":"Medicina 2026: the distinction that decides whether this becomes a liver drug — reducing fat in the liver is not the same as changing the scarring that fat drives.","claim_ids":[],"hash":"8b06faef02e21781983a0089d6c4ba36864fb9cc0de7e735a607aa1a99777b24"},{"id":"s18","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40916752/","title":"Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study","quote":"On average, people who experienced greater weight reduction also reported being less hungry and less likely to overeat.","summary":"Diabetes, Obesity & Metabolism 2025: the first study of appetite and eating behaviour on this drug. The people reporting the biggest hunger changes were the same people losing the most weight.","claim_ids":[],"hash":"9d9659b988d0f149cf0334855f280d596f2b07ab9094c61470dade787f98e93d"},{"id":"s19","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40741227/","title":"Triple Agonism Based Therapies for Obesity","quote":"Gastrointestinal symptoms were the most common side effects; no major safety concerns were observed.","summary":"The phase 2 safety picture. Phase 2 enrols hundreds of people for months — rare and long-term harms are not what it is built to detect.","claim_ids":[],"hash":"9a4af7e86f4b1875439d2ff8ad4c9bb53736b26d80756f6e3b1501ab23696277"},{"id":"s20","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40988099/","title":"Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","quote":"Pancreatic cancer and GLP-1 RA use showed no significant association (RR: 1.30, 95% CI 0.86-1.97).","summary":"Endocrinology, Diabetes & Metabolism 2025: a class-level finding for GLP-1 receptor agonists — slightly increased pancreatitis risk, no significant pancreatic cancer association. An inference for retatrutide from shared mechanism, not a measurement of it.","claim_ids":[],"hash":"5ca283da647c1cc730630d2e374aadd73bde8f5fed21a6b7e7eaa2ba42688ee9"},{"id":"s21","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40741227/","title":"Triple Agonism Based Therapies for Obesity","quote":"A comprehensive phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes in people with obesity and/or T2D.","summary":"Where the drug actually is: phase 2 complete, phase 3 running, cardiovascular and kidney outcomes not yet reported.","claim_ids":[],"hash":"cd0cad1435cf84fad1e7fac4fb2f1f9f6e906fd55bd3bc629b2e9f7e6655015a"},{"id":"s22","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41545327/","title":"The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities","quote":"Phase 2 trials report unprecedented weight reductions, comparable to bariatric surgery, with additional benefits for metabolic comorbidities such as NASH and cardiovascular disease.","summary":"Clinical Pharmacology in Drug Development 2026: a perspective calling the drug a watershed, written before any phase 3 result exists. Included as an example of the register these results attract.","claim_ids":[],"hash":"701b135b037d228e2b1825bb811eacfea9aac9936ab3b86f5127007bc4ad3409"},{"id":"s23","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41297910/","title":"Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders","quote":"These agents offer broad clinical utility beyond glucose lowering by mimicking the pleiotropic hormonal responses observed after bariatric surgery.","summary":"Clinical and Molecular Hepatology 2026: why the effects are this large. These molecules copy the several-hormone response the body produces after bariatric surgery rather than amplifying one signal.","claim_ids":[],"hash":"0d986402992fb62d477f25f9b6b7d6e3a4634c0581336bb174bc231f56fd551b"},{"id":"s24","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/","title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","quote":"490 (91%) participants completed the treatment period on study drug and 504 (94%) completed the study.","summary":"The same phase 3 trial's retention figures. For a drug whose main side effects are gastrointestinal, 91% completing on the study drug is itself a tolerability result.","claim_ids":[],"hash":"1ab5e0df5e49b2da3698bbc16b7c9ea5ae2f46b47ea53294e5c4acf46c88b54d"}],"user_reports":[],"related_articles":[{"slug":"the-disc-stack","title":"The Disc Recovery Stack","claims":[{"id":"c1","text":"The disc is the body's largest avascular structure and repairs poorly on its own, which is the central obstacle any disc-recovery strategy must overcome.","tier":"mechanistic"},{"id":"c2","text":"The body already removes most herniations: ~67% resorb spontaneously via a macrophage- and blood-vessel-driven process, so recovery means supporting an existing mechanism, not forcing a new one.","tier":"human"},{"id":"c3","text":"Body weight is a modifiable driver: overweight and obesity raise the odds of sciatica and disc herniation, making load reduction the one lever a person directly controls.","tier":"human"},{"id":"c4","text":"TNF-alpha and IL-1beta drive both disc degeneration and the inflammatory nerve pain of a herniation, making the inflammatory signal a shared target.","tier":"mechanistic"},{"id":"c5","text":"A human meta-analysis found stem-cell injection may reduce discogenic pain and disability, the first real human signal that the disc is a regeneration target - though still small and early.","tier":"human"}]},{"slug":"bpc-157","title":"BPC-157: Body Protection Compound","claims":[{"id":"c1","text":"BPC-157 is a made-in-a-lab chain of 15 amino acids, copied from a stretch of a protein found in stomach juice.","tier":"human"},{"id":"c2","text":"More than 100 studies in animals and in cells report faster healing — better-organised collagen, and blood vessels growing into the wound — across tendon, gut, muscle, bone and nerve.","tier":"preclinical"},{"id":"c3","text":"A 2025 pilot study dripped up to 20 mg of BPC-157 into the veins of two healthy adults. Nothing went wrong with their vital signs, their blood tests, or how they said they felt.","tier":"human"},{"id":"c4","text":"The proposed explanation is that BPC-157 encourages new blood vessel growth at the injury and works on the body’s nitric oxide system. That is a proposal drawn from animal work, not something measured in a person.","tier":"mechanistic"},{"id":"c6","text":"One person reported feeling sick within two weeks of starting BPC-157 and stopped taking it. That is one person. The same account was then ingested 25 more times from other copies of the same thread, and each copy is listed below so the count is visible rather than hidden.","tier":"anecdotal"},{"id":"c8","text":"The second copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 2 people.","tier":"anecdotal"},{"id":"c10","text":"The third copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 3 people.","tier":"anecdotal"},{"id":"c11","text":"Ten of the sources catalogued on this page are vendors and clinics selling BPC-157. That is marketing material, and it is listed here as marketing material rather than as evidence.","tier":"human"}]},{"slug":"tb-500","title":"TB-500: a seven-amino-acid fragment sold under the name of the protein thymosin beta-4","claims":[{"id":"c1","text":"TB-500 is sold as a made-in-a-lab version of thymosin beta-4, a small protein your own cells already make.","tier":"mechanistic"},{"id":"c300","text":"Thymosin beta-4 is the body's main handler of loose actin, the building material a cell uses to change shape and crawl.","tier":"mechanistic"},{"id":"c301","text":"Holding that building material is how thymosin beta-4 sets the pace at which cells move into an injury, and cells moving into an injury is what repair is.","tier":"mechanistic"},{"id":"c2","text":"The same seven amino acids that let thymosin beta-4 grip actin also make new blood vessels grow.","tier":"mechanistic"},{"id":"c302","text":"Those seven amino acids also make the cells that line blood vessels crawl, so new blood vessel growth is not a side effect of the repair. It is part of it.","tier":"mechanistic"},{"id":"c3","text":"In controlled animal wound experiments, thymosin beta-4 made skin grow back across the wound 42 to 61% faster than in untreated animals.","tier":"preclinical"},{"id":"c303","text":"Those same animal wounds laid down more collagen and grew more new blood vessels.","tier":"preclinical"},{"id":"c4","text":"Thymosin beta-4, the full protein rather than the fragment in the vial, was tested in people with pressure sores and long-standing leg ulcers in proper randomised, double-blind, placebo-controlled trials.","tier":"human"}]},{"slug":"ara-290","title":"ARA-290 (cibinetide): a fragment of erythropoietin that acts on nerves, not on blood","claims":[{"id":"c1","text":"ARA-290 (cibinetide) is an 11-amino-acid peptide from EPO's helix-B surface that activates the innate repair receptor (EPOR/beta-common heterocomplex) to drive tissue repair, distinct from EPO's erythropoietic receptor.","tier":"mechanistic"},{"id":"c2","text":"Because it engages the innate repair receptor rather than the homodimeric EPO receptor, ARA-290 does not stimulate erythropoiesis or raise hematocrit, avoiding EPO's thrombotic risk.","tier":"mechanistic"},{"id":"c3","text":"The mechanism was defined by Michael Brines and Anthony Cerami, who showed EPO's tissue protection runs through an EPOR/beta-common-receptor heterocomplex.","tier":"mechanistic"},{"id":"c4","text":"In a randomized, double-blind, placebo-controlled pilot in sarcoidosis patients with small-fiber neuropathy, ARA 290 significantly improved neuropathy symptom scores versus placebo.","tier":"human"},{"id":"c5","text":"In a Phase 2b RCT (n=64), 4 mg/day cibinetide significantly increased corneal nerve fiber area and raised GAP-43+ regenerating intraepidermal nerve fibers, an objective structural sign of nerve regeneration.","tier":"human"},{"id":"c6","text":"In type 2 diabetics, ARA 290 improved neuropathic symptoms alongside HbA1c and lipids over 56 days without safety issues.","tier":"human"},{"id":"c7","text":"In nerve-injury models, ARA 290 produced long-lasting, dose-dependent reductions in allodynia coupled to suppression of the spinal microglial neuroinflammatory response.","tier":"preclinical"},{"id":"c8","text":"ARA 290 inhibits macrophage activation and pro-inflammatory cytokine release (IL-6, IL-12, TNF-alpha) and protects cells from cytokine-induced apoptosis.","tier":"preclinical"}]},{"slug":"degenerative-disc-disease","title":"Degenerative Disc Disease","claims":[{"id":"c1","text":"Degeneration starts as a failure to hold water. The soft centre of the disc loses aggrecan, the molecule that pins water in place, and the water leaves with it.","tier":"mechanistic"},{"id":"c320","text":"A disc is roughly 90% water at birth and around 70% by age 60. Once it is that dry it can no longer hold pressure and share the load the way it is supposed to.","tier":"mechanistic"},{"id":"c2","text":"The disc heals badly because it is the largest structure in the body with no blood supply of its own. Everything it needs seeps slowly in through the bony plates above and below it.","tier":"mechanistic"},{"id":"c3","text":"Once the centre has dried out, the load shifts onto the tough outer ring, which starts to crack and tear. The disc does try to repair itself, but the breaking down keeps running ahead of the repair.","tier":"mechanistic"},{"id":"c4","text":"Two inflammatory signals, TNF-alpha and IL-1beta, do most of the driving in disc degeneration and in pain that comes from the disc itself. The disc's own cells are what make them.","tier":"mechanistic"},{"id":"c321","text":"Those same two signals coax nerve fibres to grow into a disc that in health has no nerves inside it at all.","tier":"mechanistic"},{"id":"c5","text":"In a controlled rat study, injecting TNF-alpha produced both pain and degeneration, and blocking it at the moment of injury stopped both from appearing. That makes TNF-alpha a cause and not just a marker.","tier":"preclinical"},{"id":"c6","text":"TNF-alpha tips the disc's building-and-breaking balance towards breaking. It raises the enzymes that chew up the disc's scaffolding, called MMPs, faster than it raises the TIMPs that hold those enzymes back.","tier":"mechanistic"}]}],"question_graph":{"slug":"retatrutide","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":7,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":7,"claims_total":7,"sources":24,"anecdotal":0,"scientific":24,"user_reports":0,"questions":0,"evidence_ingests":0}}